Cognoptix has created a noninvasive eye-scanning device, called SAPPHIRE II, that uses a specific beta amyloid signature in the eye to determine whether a patient is at risk for Alzheimer's disease. The Acton, Mass.-based company will release information on the device Wednesday at a conference in Boston.
Eye-scanning device is designed to detect Alzheimer's disease
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore